Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

By          

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 208-214

Spandidos Publications

Access to resources Recommend Favorite

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

By Crafter Claire   Vincent John P.   Tang Eric   Dudley Phillippa   James Neil H.   Klinowska Teresa   Davies Barry R.  

International Journal of Oncology, Vol. 47, Iss. 2, 2015-08 ,pp. : 446-454

Spandidos Publications

Access to resources Recommend Favorite

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

By Lipton Allan   Goodman Laurie   Leitzel Kim   Cook Jennifer   Sperinde Jeff   Haddad Mojgan   Köstler Wolfgang   Huang Weidong   Weidler Jodi   Ali Suhail   Newton Alicia   Fuchs Eva-Marie   Paquet Agnes   Singer Christian   Horvat Reinhard   Jin Xueguang   Banerjee Joyee   Mukherjee Ali   Tan Yuping   Shi Yining   Chenna Ahmed   Larson Jeff   Lie Yolanda   Sherwood Thomas   Petropoulos Christos   Williams Stephen   Winslow John   Parry Gordon   Bates Michael  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 43-53

Springer Publishing Company

Access to resources Recommend Favorite

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

By Wei Qichun  

Annals of Surgical Oncology, Vol. 15, Iss. 4, 2008-04 ,pp. : 1193-1201

Springer Publishing Company

Access to resources Recommend Favorite

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite